CI-966

CAS No. 110283-79-9

CI-966( PD 126141 )

Catalog No. M10395 CAS No. 110283-79-9

CI-966 (PD 126141) is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CI-966
  • Note
    Research use only, not for human use.
  • Brief Description
    CI-966 (PD 126141) is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively.
  • Description
    CI-966 (PD 126141) is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively; displays >200-fold selectivity over GAT-2 and GAT-3; shows anticonvulsive and neuroprotective activity in vivo.Epilepsy Phase 1 Discontinued.
  • In Vitro
    CI-966 functions by selectively inhibiting GABA reuptake in neurons and glial cells.
  • In Vivo
    CI-966 produces intermediate levels of Pentylenetetrazol (PTZ)-lever responding when administered to PTZ-trained rats.CI-966 enhances gamma-aminobutyric acid action in CA1 pyramidal layer in situ. CI-966 is administered systemically by i.p. injection (5 mg/kg) in Sprague-Dawley rats under urethane anaesthesia. Twenty to thirty minutes after injection there is a highly variable, but overall significant, enhancement of the inhibition of hippocampal population spikes by GABA applied by microiontophoresis in the CA1 region. CI-966 exhibits anticonvulsant properties in various animal models. Oral absorption of CI-966 in dogs given 1.39 mg/kg is rapid with a tmax of 0.7 hr.In rats given 5 mg/kg oral, a mean tmax of 4.0 hr is observed. Following i.v. administration of the same respective doses, elimination t1/2 in dogs and rats averages 1.2 and 4.5 hr. Absolute oral bioavailability of CI-966 is 100% in both species. Animal Model:Eight male Sprague-Dawley rats Dosage:0.3-30 mg/kg Administration:Injection IP in a volume of 1 mL/kg Result:Dose dependent decreases in rates of responding occurred following CI-966 administration.
  • Synonyms
    PD 126141
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    GAT
  • Recptor
    GAT
  • Research Area
    Neurological Disease
  • Indication
    Epilepsy

Chemical Information

  • CAS Number
    110283-79-9
  • Formula Weight
    473.415
  • Molecular Formula
    C23H21F6NO3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C1CN(CC(=C1)C(=O)O)CCOC(C2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F
  • Chemical Name
    1-[2-[bis[4-(Trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydropyridine-3-carboxylic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ebert U, et al. Can J Physiol Pharmacol. 1990 Sep;68(9):1194-9. 2. Radulovic LL, et al. Pharm Res. 1993 Oct;10(10):1442-5. 3. Phillis JW. Gen Pharmacol. 1995 Sep;26(5):1061-4.
molnova catalog
related products
  • Alprazolam

    Alprazolam (D-65MT;U 31889) is a triazolobenzodiazepine agent with anxiolytic, sedative-hypnotic and anticonvulsant activities.

  • Indiplon

    A potent GABAA receptor positive allosteric modulator that acts at the benzodiazepine site.

  • AZD6280

    AZD6280 is a potent, α2/3 functionally selective, partial GABAA receptor modulator with pKi of 7.7.